Newsroom

September 24, 2020

A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling canine flea infestations

Abstract Background: The novel isoxazoline molecule fluralaner provides 12 weeks activity against fleas and 8 to 12 weeks against tick infestations according to label claims. Methods: This blinded, multi-center study in client-owned dogs evaluated the flea control provided by a single oral fluralaner treatment (25–56 mg/kg; Bravecto™, Merck Animal Health) compared to a control group […]

September 24, 2020

The effect of food on the pharmacokinetics on oral fluralaner in dogs

Abstract Background: Fluralaner is a novel systemic ectoparasiticide for dogs providing long-acting flea- and tick-control after a single oral dose. The pharmacokinetics of orally administered drugs may be influenced by feeding. This study investigated the influence of concurrent feeding on fluralaner pharmacokinetics. Methods: Twelve fasted or fed beagles received a single oral administration of 25 […]

September 24, 2020

Pharmacokinetics of fluralaner in dogs following a single oral or intravenous administration

Abstract Background: Fluralaner is a novel systemic insecticide and acaricide. The purpose of these studies was to investigate the pharmacokinetic properties of fluralaner in Beagle dogs following single oral or intravenous (i.v.) administration. Methods: Following the oral administration of 12.5, 25 or 50 mg fluralaner/kg body weight (BW), formulated as chewable tablets or i.v. administration […]

September 24, 2020

Plasma pharmacokinetic profile of fluralaner (BRAVECTO™) and ivermectin following concurrent administration to dogs

Abstract Background: Fluralaner is a novel systemic ectoparasiticide for dogs providing immediate and persistent flea, tick and mite control after a single oral dose. Ivermectin has been used in dogs for heartworm prevention and at off label doses for mite and worm infestations. Ivermectin pharmacokinetics can be influenced by substances affecting the p-glycoprotein transporter, potentially […]

September 24, 2020

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling canine flea infestations

Abstract Background: Orally administered fluralaner effectively controls fleas and ticks on dogs for 12 weeks. This study evaluates the flea control efficacy achieved with topically applied fluralaner in dogs. Methods: This investigator-blinded, multi-center randomized, positive controlled study evaluated flea control efficacy in dogs following a single owner-applied treatment of topical fluralaner. A positive control group […]

September 24, 2020

The effect of water and shampooing on the efficacy of fluralaner spot-on solution against Ixodes ricinus and Ctenocephalides felis infestations in dogs

Abstract Background: Fluralaner spot-on solution provides immediate and persistent efficacy against tick and flea infestations in dogs and cats for 12-weeks following topical administration. The active ingredient fluralaner is distributed systemically following transdermal absorption. Therefore, this study tested the hypothesis whether water-immersion or shampooing of dogs following administration of fluralaner spot-on solution has an impact […]

August 25, 2020

COMPETITIVE COMPARISON

ONLY NOBIVAC® LYME OFFERS POWERFUL COMPARATIVE BENEFITS AND PROVEN SAFETY.

August 24, 2020

Three-Year Duration of Immunity in Dogs Following Vaccination Against Canine Adenovirus Type-1, Canine Parvovirus, and Canine Distemper Virus

Clinical Relevance A challenge-of-immunity study was conducted to demonstrate immunity in dogs 3 years after their second vaccination with a new multivalent, modified-live vaccine containing canine adenovirus type-2, canine parvovirus (CPV), and ca-nine distemper virus (CDV). Twenty-three seronegative pups were vaccinated at 7 and 11 weeks of age. Eighteen seronegative pups, randomized into groups of […]